Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of cefepime-induced encephalopathy in a patient with depression and rectal cancer: A case report.
Neuropsychopharmacol Rep
March 2025
National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- Cefepime, a fourth-generation antibiotic, can cause neurotoxic side effects like encephalopathy, particularly in patients with compromised blood-brain barriers (BBB) and renal issues.
- A case study of a 79-year-old woman with depression and cancer demonstrated that after receiving cefepime, she developed confusion and other neurological symptoms without apparent brain damage or kidney dysfunction.
- The case suggests that depression and cancer may increase the risk of cefepime-induced encephalopathy, highlighting the need for doctors to monitor such patients closely to avoid misdiagnosis and ensure proper treatment.
Cefepime is a fourth-generation cephalosporin antibiotic administered intravenously used to treat various bacterial infections, including urinary tract infections. Administering cefepime to patients should be done with caution, understanding both potential risks and side effects. A 74-year-old female presented to the family medicine clinic with abdominal pain and a history of urinary tract infections.
View Article and Find Full Text PDFCefepime Neurotoxicity in Patients With Normal Renal Function: An Overlooked Cause of Encephalopathy in the Intensive Care Unit.
J Investig Med High Impact Case Rep
July 2024
Joan Edwards School of Medicine, Huntington, WV, USA.
Article Synopsis
- - Cefepime, a fourth-generation antibiotic, has extended antimicrobial capabilities but can cause serious side effects like myoclonus and seizures, particularly in patients with kidney issues.
- - A 69-year-old patient treated with cefepime for pneumonia experienced mental status changes that led to the diagnosis of encephalopathy, even with normal kidney function.
- - The patient's symptoms completely resolved after stopping cefepime, and the report includes similar cases found in medical literature up to now.
Cefepime-induced encephalopathy in an older patient with polypharmacy and renal insufficiency: a case report.
J Int Med Res
May 2024
Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
The world population is rapidly aging. Societal aging poses many challenges for individuals, families, nations, and the global healthcare system. Therefore, geriatric care is a crucial issue that demands our attention.
View Article and Find Full Text PDFDanger in plain sight: determining who is at highest risk for cefepime induced neurotoxicity and its associated morbidity and mortality.
Acta Neurol Belg
December 2024
Department of Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Cefepime is a fourth-generation cephalosporin that is widely used to treat sepsis but is associated with a potentially dangerous neurotoxicity syndrome, cefepime-induced neurotoxicity (CIN). As a result, patients treated with cefepime may be at higher risk for morbidity, including seizures, and mortality. Though the recent ACORN trial concluded that cefepime does not increase the risk of mortality, most of these patients were not critically ill or elderly, two of the most at risk populations for CIN.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!